Easily Upgradable Parallel Synthesis Products
Asynt has designed its range of products for parallel synthesis to share standard parts (inserts) for reaction tube, vial and round-bottom flask based reactions. Consequently investment in an entry level DrySyn Parallel Synthesis kit provides you with an easy upgrade path to the advanced capabilities of a DrySyn Snowstorm system.
The DrySyn Parallel Synthesis Kit provides a convenient, low cost solution for chemists wishing to conduct simple synthetic reactions with temperature control and magnetic stirring, but without the complications of reflux or inerting. The kit accommodates a range of standard reaction tubes and vials of different diameters. It can also be upgraded to a parallel reaction station using standard round-bottom flasks, by using the appropriate DrySyn MULTI inserts. In this configuration, facilities can be added such as directly driven stirring with the Asynt Vortex stirrer system.
Available in a choice of configurations, an Asynt DrySyn SnowStorm system provides controlled cooling and heating for sub-ambient parallel chemistry without the need for jacketed reaction vessels or ice baths. Operating with a suitable chiller/circulator, a DrySyn SnowStorm system provides accurate, stable temperature control down to -50 °C and up to +150 °C, making it the perfect tool for crystallisation studies and screening polymorphs.
Related News
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance